Haloperidol and Gemcitabine drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Haloperidol (haloperidol) and Gemcitabine (gemcitabine). Common drug interactions include hypophagia among females and haemoglobin decreased among males.

The phase IV clinical study analyzes what interactions people have when they take Haloperidol and Gemcitabine. It is created by eHealthMe based on reports of 35 people who take the same drugs from the FDA, and is updated regularly.

What is Haloperidol?

Haloperidol has active ingredients of haloperidol. It is often used in schizophrenia. eHealthMe is studying from 16,637 Haloperidol users. Check the latest studies of Haloperidol.

What is Gemcitabine?

Gemcitabine has active ingredients of gemcitabine. eHealthMe is studying from 31,337 Gemcitabine users. Check the latest studies of Gemcitabine.



On Jul, 16, 2026

35 people who take Haloperidol and Gemcitabine together, and have interactions are studied.

Haloperidol and Gemcitabine drug interactions.

What are the common drug interactions of Haloperidol and Gemcitabine, by gender? *:

female:

  1. Hypophagia (reduced food intake)
  2. Mental disorder (a psychological term for a mental or behavioural pattern or anomaly that causes distress or disability)
  3. Neuralgia (pain in one or more nerves)
  4. Oedema peripheral (superficial swelling)
  5. Prothrombin time shortened
  6. Suicide attempt
  7. Abdominal pain
  8. Intestinal perforation (complete penetration of the wall of the intestine)
  9. Bile duct stenosis (abnormal narrowing of the common bile duct)
  10. Drug ineffective

male:

  1. Haemoglobin decreased
  2. Ascites (accumulation of fluid in the abdominal cavity)
  3. Haemorrhagic cerebral infarction (brain stroke with bleeding)
  4. Blood creatine increased
  5. Blood potassium increased
  6. Blood urea increased
  7. Disease progression
  8. Disorientation (disability in which the senses of time, direction, and recognition of people and places)
  9. Duodenal obstruction (partial or complete obstruction of the duodenum)
  10. Dysarthria (speech disorder)

What are the common drug interactions of Haloperidol and Gemcitabine, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

  1. Stent occlusion (blockage of stent)
  2. Cholangitis (infection of the bile duct)

40-49:

  1. Ascites (accumulation of fluid in the abdominal cavity)
  2. Haemoglobin decreased
  3. Ileus (a painful obstruction of the ileum or other part of the intestine)
  4. Intestinal fistula
  5. Disease progression
  6. Drug ineffective
  7. Pyrexia (fever)
  8. Thrombocytopenia (decrease of platelets in blood)
  9. Upper gastrointestinal haemorrhage (upper gastrointestinal bleeding)
  10. Aspartate aminotransferase increased

50-59:

  1. Anaemia (lack of blood)
  2. Constipation
  3. Lethargy (tiredness)
  4. Mental status changes (general changes in brain function, such as confusion, amnesia (memory loss), loss of alertness, loss of orientation)
  5. Pulmonary embolism (blockage of the main artery of the lung)
  6. Renal cyst (kidney cyst)
  7. Renal failure (kidney dysfunction)
  8. Urinary tract pain
  9. Back pain
  10. Bile duct obstruction (blockage in the tubes that carry bile from the liver to the gallbladder)

60+:

  1. Delirium (wild excitement)
  2. Intestinal perforation (complete penetration of the wall of the intestine)
  3. Disorientation (disability in which the senses of time, direction, and recognition of people and places)
  4. Duodenal obstruction (partial or complete obstruction of the duodenum)
  5. Dysarthria (speech disorder)
  6. Extrapyramidal disorder (involuntary muscle spasms in the face and neck)
  7. Faecal incontinence (a lack of control over passing stool)
  8. Grand mal convulsion (a type of generalized seizure that affects the entire brain)
  9. Intestinal obstruction
  10. Pneumonia aspiration (bronchopneumonia that develops due to the entrance of foreign materials into the bronchial tree)

What are the existing conditions these people have? *

  1. Pancreatic Carcinoma Metastatic (pancreatic cancer- metastatic): 10 people, 28.57%
  2. Pain: 7 people, 20.00%
  3. Nausea (feeling of having an urge to vomit): 7 people, 20.00%
  4. High Blood Pressure: 6 people, 17.14%
  5. Indigestion: 4 people, 11.43%
  6. Stomatitis (inflammation of mucous membrane of mouth): 4 people, 11.43%
  7. Constipation: 4 people, 11.43%
  8. Nausea And Vomiting: 4 people, 11.43%
  9. Cholangiocarcinoma (a cancer that forms glands or secretes significant amounts of mucins): 4 people, 11.43%
  10. Lung Cancer - Non-Small Cell (lung cancer): 4 people, 11.43%

* Approximation only. Some reports may have incomplete information.

Do you take Haloperidol and Gemcitabine?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Haloperidol and Gemcitabine:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Haloperidol:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Gemcitabine:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Haloperidol and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Gemcitabine and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Related publications that referenced our studies


How the study uses the data?

The study uses data from the FDA. It is based on haloperidol and gemcitabine (the active ingredients of Haloperidol and Gemcitabine, respectively), and Haloperidol and Gemcitabine (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: